Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

Aim: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. Methods: In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurr...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank PK Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil EJC Schijns, Apostolos Stathopoulos
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Taylor & Francis Group 2018-07-01
Sarja:	CNS Oncology
Aiheet:	allogeneic autologous bevacizumab CD4+ T lymphocyte ERC1671 GBM
Linkit:	https://www.futuremedicine.com/doi/10.2217/cns-2018-0009
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!